Rivaroxaban is a direct oral anticoagulant (DOAC) drug used to treat and prevent blood clots in the lungs. It is used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), two conditions that can lead to serious respiratory complications. Rivaroxaban works by inhibiting the activity of Factor Xa, an enzyme involved in the clotting process. It is also used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Rivaroxaban is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2011. It is now widely used in the treatment of respiratory conditions, and is increasingly being prescribed as a first-line treatment for DVT and PE. Rivaroxaban is generally well-tolerated and has fewer drug interactions than other DOACs. Companies in the Rivaroxaban market include Bayer AG, Janssen Pharmaceuticals, and Daiichi Sankyo. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
